Biocon gets DCGI nod for device to treat critical COVID-19 patients

The company has been granted licence for emergency use of CytoSorb, an extracorporeal blood purification device CytoSorb to reduce pro-inflammatory cytokines levels, to treat COVID-19 patients who are 18 years of age or older.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3gl5P7H
via IFTTT